The front page of AI-driven biology
Monday, October 19, 2026Mon, Oct 19
Updated 12:01 PM PT
London-based IMU Biosciences and UK Biobank have launched an initiative to profile immune cells and gene expression across an initial cohort of 80,000 participant blood samples, with plans to expand across the full 500,000-person biobank.
The FDA cleared GlaxoSmithKline's PD-1 inhibitor Jemperli (dostarlimab-gxly) as monotherapy for adults with untreated, locally advanced stage II or III rectal cancer whose tumors lack DNA mismatch repair machinery (dMMR or MSI-H).
Shares in EyePoint tumbled over 84% after its Phase 3 Lucia trial evaluating Duravyu in wet age-related macular degeneration missed its goals.
Sanofi has entered its first collaboration with startup ScionxBio to screen long-acting messenger RNA candidates using the company's proprietary TERA platform.
Disc Medicine reported that bitopertin, an oral small-molecule glycine transporter 1 inhibitor, met its primary and secondary endpoints in a pivotal clinical trial for erythropoietic protoporphyria.
Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash buyout valuing the RNA-interference specialist at $20.00 per American depositary share.
Roche will pay Hansoh Pharmaceutical $400 million upfront and $110 million at the one-year mark to partner on multiple antibody-drug conjugate programs.
Eli Lilly formed a research collaboration with Hong Kong-listed Metis TechBio valued at up to $1.1 billion to discover and develop tissue-specific delivery vehicles for therapeutics.
TriGemX Bio, previously known as Kallyope, agreed to merge with the special purpose acquisition company TCGX in a transaction valued at $600 million.
AbbVie said its experimental combination of the interleukin-23 inhibitor Skyrizi and the alpha-4-beta-7 integrin blocker trosunilimab produced a 30.2% endoscopic remission rate at 12 weeks in a Phase 2 trial of 300 Crohn's disease patients.
Patients receiving a 200 milligram daily dose of emvistegrast achieved a 23% placebo-adjusted clinical remission rate after 12 weeks of treatment.
Benchmarking of the CORNETO framework evaluated how effectively computational models infer biological networks across multiple molecular profiling datasets.
Researchers developed SPACER, an interpretable neural network that learns the biochemical rules governing cell recruitment directly from spatial transcriptomics data.
Computational biologists introduced DCAF, an integrated computational framework designed to pair optimal-transport data reconstruction with joint-embedding predictive architectures for single-cell perturbation modeling.
RegDesign-Bench systematically evaluated computational methods intended to design synthetic cis-regulatory DNA sequences that turn genes on in specific cell types.
Researchers introduced LineageFlow, a computational method that combines continuous cell-state transitions with relative expansion rates to predict how early single cells differentiate.
Researchers combined the general vision model SAM3 with the pathology-specific model UNI2-h to create TiSAM, an architecture designed to segment complex tissue structures in whole-slide histology images.
Researchers introduced causal integrated gradients, an explainable machine learning algorithm that routes integration paths along known biological network graphs.
Researchers built Brieflow-auto, an agent harness using Claude Code that automatically runs an open-source image analysis pipeline for optical pooled screening experiments.
Researchers built PINATA, a computational model that uses evolutionary alignments across related species to choose DNA codons when translating a protein sequence back into nucleic acids.